Prognosis
Covid Boosters Sour for Pfizer, Moderna With Uptake Rate at 16%
- Seven of 13 experts surveyed see no improvement in rates
- Pfizer and Moderna have billions riding on booster demand
This article is for subscribers only.
When Covid-19 vaccines first gained approval two years ago, Pfizer Inc. and Moderna Inc. didn’t have to worry about demand. Now, billions of dollars ride on a picture that is murkier than ever.
People lined up overnight in the pandemic’s early stages for doses that companies couldn’t make fast enough. Almost 70% of Americans got vaccinated in the first inoculation drive. But uptake for booster shots has dropped in almost every cycle since, and just 16% got the latest round of shots targeting the omicron variant.